Susquehanna International Group
GANX icon

Susquehanna International Group’s Gain Therapeutics GANX Stock Holding History

Susquehanna International Group’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$837K Sell
431,267
-253,082
-37% -$551K ﹤0.01% 8369
2025
Q4 		$2.2M Buy
684,349
+603,914
+751% +$1.61M ﹤0.01% 5449
2025
Q3 		$142K Buy
80,435
+884
+1% +$1.49K ﹤0.01% 11321
2025
Q2 		$143K Sell
79,551
-6,407
-7% -$11.8K ﹤0.01% 11533
2025
Q1 		$164K Buy
85,958
+39,045
+83% +$86.6K ﹤0.01% 11137
2024
Q4 		$101K Buy
+46,913
New +$94.2K ﹤0.01% 11337
2024
Q2 		– Sell
-43,062
Closed -$162K – 12429
2024
Q1 		$162K Buy
43,062
+8,562
+25% +$35.5K ﹤0.01% 10829
2023
Q4 		$113K Sell
34,500
-30,726
-47% -$85.4K ﹤0.01% 11228
2023
Q3 		$211K Sell
65,226
-4,564
-7% -$17.3K ﹤0.01% 10121
2023
Q2 		$313K Buy
69,790
+54,618
+360% +$267K ﹤0.01% 9347
2023
Q1 		$73.1K Buy
+15,172
New +$62K ﹤0.01% 11508
2022
Q1 		– Sell
-19,357
Closed -$103K – 13332
2021
Q4 		$103K Buy
+19,357
New +$134K ﹤0.01% 12127

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group's GANX Position: Q1 2026 in Review

Susquehanna International Group reduced its Gain Therapeutics (GANX) stake by 37% in Q1 2026, selling an estimated $551K and leaving 431,267 shares worth $837K. The position accounts for ﹤0.01% of the portfolio, ranked #8369.

Susquehanna International Group first reported a position in GANX in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.2M in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Susquehanna International Group held 431,267 shares of Gain Therapeutics worth $837K as of Q1 2026.
  • Susquehanna International Group sold 253,082 Gain Therapeutics shares in Q1 2026, an estimated $551K.
  • Gain Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8369 holding.
  • Susquehanna International Group first reported a position in Gain Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Susquehanna International Group's Gain Therapeutics position peaked at $2.2M in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.